|0.4351 -0.036 (-7.64%)||11-28 13:35|
|Targets||6-month :||0.91||1-year :||1.16|
|Resists||First :||0.78||Second :||0.99|
|Supports||First :||0.43||Second :||0.35|
|MAs||MA(5) :||0.48||MA(20) :||0.53|
|MA(100) :||0.82||MA(250) :||4.5|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||2.3||D(3) :||3.6|
|52-week||High :||13.19||Low :||0.43|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BBLG ] has closed above bottom band by 19.1%. Bollinger Bands are 0.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||0.49 - 0.5||0.5 - 0.5|
|Low:||0.45 - 0.46||0.46 - 0.46|
|Close:||0.47 - 0.47||0.47 - 0.48|
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Fri, 17 Nov 2023
Financings for Nov. 17, 2023 - BioWorld Online
Thu, 16 Nov 2023
Why Is Augmedix (AUGX) Stock Down 27% Today? - InvestorPlace
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||4 (M)|
|Shares Float||3 (M)|
|Held by Insiders||13.6 (%)|
|Held by Institutions||3.2 (%)|
|Shares Short||9 (K)|
|Shares Short P.Month||15 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||1.21|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-117.4 %|
|Return on Equity (ttm)||-158.8 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-9 (M)|
|Levered Free Cash Flow||-6 (M)|
|Price to Book value||0.36|
|Price to Sales||0|
|Price to Cash Flow||-0.2|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|